The XXXIX cycle of the Ph.D course in Experimental and Translational Medicine aims at applying an interdisciplinary approach to human health to allow a valuable transfer of the most recent developments in basic sciences to the clinical practice. The main goal of the course is to overcome the compartmentalization often encountered between basic and medical sciences as a consequence of the obviously different experimental approaches used and to enable the Ph.D. student to acquire multiple technical skills, learn a scientific interdisciplinary approach (including cellular biology, genetics, immunology, microbiology, physiology and neurosciences) and successfully export these knowledges to the prevention, diagnosis, and treatment of a panorama of clinical pathologies. Indeed, although Translational Medicine is experimental by nature, it must be developed keeping in mind its potential impact on the improvement of human health.
The Ph.D. student will be asked to carry on an experimental study using specific and innovative technological tools, to adequately interpret the results of the study and to learn several aspects of the clinical research approaches in order to develop his/her own skill in evaluating the applicability of new technologies to clinical research.
More specifically, the targets of the XXXIX cycle of the Ph.D course are to provide the student with the know-how:

• to fully develop the research project chosen among those proposed for the XXXVIII cycle and to master the experimental procedures needed to solve potential experimental difficulties
• to adequately interpret and discuss the obtained results, to write scientific reports and to present the data to the scientific community at national and international meetings
• to be able to experience a period (6-18 months) of research in a highly qualified foreign research institution
• to prepare the final thesis and to present and discuss it with a Commission of experts at national and international levels.

The Ph.D. in Experimental and Translational Medicine will be qualified for the Academic and Health Care community, for private and public research Institutions and for biotechnological industries